Johnson & Johnson (JNJ), the world's biggest health-care products maker is set to report first-quarter results before the bell Tuesday. The firm is still struggling with drug-recall and quality-control problems as well as liabilities arising out of continued litigations.
Analysts expect earnings of $1.36 a share compared with $1.25 a year ago.
Investors will want clarity over a number of issues, including a $1.1 billion penalty imposed just last week by an Arkansas jury that found the company guilty of misleading doctors and patients about the risks of the antipsychotic drug Risperdal.
For the longer term, Morningstar analyst Damien Conover feels the company's strong pipeline of products and minimal patent losses (further aided by the $21 billion acquisition of Synthes) are supportive of a steady outlook.
After a 3% drop in its share price year to date, the stock is trading at a discount to Conover's fair value estimate. However, J&J still needs to overcome several roadblocks and be careful about any potential damage to its reputation.
发表于 2012-4-17 01:54
| 
发表于 2012-4-17 08:52
|